Mesalazine ( DrugBank: Mesalazine )

3 diseases

ID	Disease name (Link within this page)	Number of trials
46	Malignant rheumatoid arthritis	1
96	Crohn disease	29
97	Ulcerative colitis	237

46. Malignant rheumatoid arthritis

Clinical trials : 4,356 / Drugs : 2,567 - (DrugBank : 415) / Drug target genes : 192 - Drug target pathways : 228

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-UMIN000005362	2011/04/01	01/04/2011	Clinical study for the efficacy of mesalazinefor the treatment of small bowel injury caused by non-s ...	Clinical study for the efficacy of mesalazinefor the treatment of small bowel injury caused by non-s ...	Patients with rheumatoid arthritis with anemia taking NSAIDs	Treatment with mesalazine	Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine	NULL	Complete: follow-up complete	20years-old	70years-old	Male and Female	13	Not selected	Japan

First Previous1Next Last

96. Crohn disease

Clinical trials : 2,442 / Drugs : 1,278 - (DrugBank : 248) / Drug target genes : 142 - Drug target pathways : 209

diseases per page:

Showing 1 to 10 of 29 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05386290 (ClinicalTrials.gov)	July 9, 2020	17/5/2022	A Multicentered Prospective Cohort Study of Chinese IBD Patients	A Multicentered Prospective Cohort Study of Chinese IBD Patients Concerning Cost-effectiveness Analy ...	Ulcerative Colitis;Crohn Disease	Drug: Infliximab;Drug: Vedolizumab;Drug: Ustekinumab;Drug: conventional treatment (glucocoticoid, im ...	Peking Union Medical College Hospital	NULL	Enrolling by invitation	14 Years	80 Years	All	200		China
2	EUCTR2018-001382-17-GB (EUCTR)	30/10/2018	24/06/2019	An investigational study to assess the safety and effectiveness of continuing existing 5-ASA medicat ...	Stopping Aminosalicylate Therapy in Inactive Crohn’s Disease (STATIC) Study: A Randomized, Open-labe ...	Inactive Crohn’s Disease;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	INN or Proposed INN: MESALAZINE	Alimentiv Inc	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	1580	Phase 4	Canada;United Kingdom
3	NCT02769494 (ClinicalTrials.gov)	March 2016	9/3/2016	The Efficacy of Topical MesalazineSustained-Release Tablets in Crohn's Disease Patients With Oral Ul ...	The Efficacy of Topically Applied MesalazineSustained-Release Tablets in Oral Lesions of Crohn's Dis ...	Crohn's Disease;Oral Ulcer	Drug: Mesalazine Sustained-Release Tablets;Drug: Riboflavin Sodium Phosphate Injection	Xijing Hospital of Digestive Diseases	NULL	Withdrawn	18 Years	65 Years	All	0	Phase 3	China
4	NCT02335281 (ClinicalTrials.gov)	January 2015	7/1/2015	Standardized Fecal Microbiota Transplantation for Inflammatory Bowel Disease	Efficacy, Durability and Safety of Standardized Fecal Microbiota Transplantation for Severe Inflamma ...	Inflammatory Bowel Disease;Ulcerative Colitis;Crohn's Disease	Procedure: FMT;Drug: Mesalazine	Yanling Wei	NULL	Recruiting	16 Years	70 Years	Both	40	Phase 2	China
5	NCT02044952 (ClinicalTrials.gov)	January 2014	19/1/2014	Efficacy and Safety Study of Tripterygium Glycoside in the Treatment of Crohn's Disease for Inductio ...	Prospective Experimental of Tripterygium Glycoside in the Treatment of Crohn's Disease for Induction ...	Inflammatory Bowel Diseases;Crohn's Disease;Gastrointestinal Diseases;Digestive System Diseases;Inte ...	Drug: Mesalazine, Tripterygium glycosides	Zhu Weiming	NULL	Recruiting	18 Years	75 Years	Both	40	Phase 2/Phase 3	China
6	NCT01514240 (ClinicalTrials.gov)	February 2012	10/1/2012	Phase III Study of D9421-C 9 mg in Patients With Active Crohn's Disease in Japan	A Multicentre, Double-blind, Randomised, Parallel-group, Phase III Study to Assess Efficacy and Safe ...	Crohn's Disease	Drug: D9421-C capsule 3 mg;Drug: Mesalazine tablets	AstraZeneca	NULL	Completed	15 Years	130 Years	All	123	Phase 3	Japan
7	EUCTR2009-011220-62-NL (EUCTR)	26/10/2009	13/07/2009	A randomized controlled withdrawal trial in Crohn's disease patients in long-term remission on mesal ...	A randomized controlled withdrawal trial in Crohn's disease patients in long-term remission on mesal ...	1. Patients with a diagnosis of quiscent (CDAI < 150) Crohn's Disease (CD) according to established ...	Product Name: mesalazine INN or Proposed INN: mesalazine Other descriptive name: AMINOSALICYLIC ACID	University Medical Center Utrecht	NULL	Not Recruiting			Female: yes Male: yes			Netherlands
8	NCT00862121 (ClinicalTrials.gov)	April 2009	13/3/2009	A Study With Pentasa in Patients With Active Crohn's Disease	PENTASA in Active Crohn's Disease: A 10-week, Double-blind, Multi-centre Trial Comparing PENTASA Sac ...	Crohn´s Disease	Drug: Pentasa;Drug: Placebo	Ferring Pharmaceuticals	NULL	Terminated	18 Years	N/A	All	20	Phase 3	United States;Belgium;Denmark;France;Germany;Sweden;United Kingdom;Spain
9	NCT00245505 (ClinicalTrials.gov)	February 2009	26/10/2005	The Effect on Mucosal Healing With Pentasa Sachet in Mild to Moderate Active Drug: Crohn's Disease	The Effect on Mucosal Healing With Pentasa Sachet 4g in Mild to Moderate Active Small Bowel Crohn´s ...	Crohn's Disease	Drug: Mesalazine (Mesalamine)	Ferring Pharmaceuticals	NULL	Terminated	18 Years	70 Years	Both	3	Phase 3	Sweden
10	EUCTR2008-002100-26-BE (EUCTR)	28/01/2009	31/07/2008	PENTASA in active Crohn’s Disease: A 10-week, double-blind, multi-centre trial comparing PENTASA Sac ...	PENTASA in active Crohn’s Disease: A 10-week, double-blind, multi-centre trial comparing PENTASA Sac ...	Active mild to moderate crohn's disease. MedDRA version: 9.1;Level: LLT;Classification code 10011401 ...	Trade Name: PENTASA Sachet INN or Proposed INN: MESALAZINE Other descriptive name: Mesalamine, 5-amino ...	Ferring Pharmaceuticals A/S	NULL	Not Recruiting			Female: yes Male: yes	510		France;Belgium;Denmark;Germany;United Kingdom;Sweden

First Previous1 2 3Next Last

97. Ulcerative colitis

Clinical trials : 2,630 / Drugs : 1,459 - (DrugBank : 265) / Drug target genes : 144 - Drug target pathways : 202

diseases per page:

Showing 1 to 10 of 237 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05561062 (ClinicalTrials.gov)	December 1, 2022	27/9/2022	Atorvastatin in Patients With Ulcerative Colitis	Combination of Atorvastatin and Mesalazineto Enhance Anti-inflammatory Effects and Attenuates Progre ...	Inflammatory Bowel Diseases	Drug: Atorvastatin 80mg	Tanta University	NULL	Not yet recruiting	18 Years	75 Years	All	50	Phase 2	NULL
2	ITMCTR2200006063	2022-06-05	2022-06-05	A systematic study on the syndrome differentiation standard of lingnan wet syndrome - ulcerative col ...	A systematic study on the syndrome differentiation standard of lingnan wet syndrome - ulcerative col ...	Ulcerative colitis	No intervention:No intervention;Pure western medicine intervention:Mesalazine;Intervention of integr ...	Guangdong Provincial Hospital of Chinese Medicine	NULL	Pending	18	75	Both	No intervention:25;Pure western medicine intervention:25;Intervention of integrated Chinese and Western medicine:25;Simple Chinese medicine intervention:25;	Phase 1	China
3	ChiCTR2200059150	2022-05-05	2022-04-26	Study on the mechanism of Qingchangxiaopi Decoction and UC large intestine damp-heat syndrome from t ...	Study on the mechanism of Qingchangxiaopi Decoction and UC large intestine damp-heat syndrome from t ...	Ulcerative colitis (UC)	Intervention group:Qingchangxiaopi Decoction;Control group:Mesalazine;	Dongguan Hospital of Guangzhou University of Chinese Medinine	NULL	Pending	18	70	Both	Intervention group:30;Control group:30;		China
4	ITMCTR2100005038	2021-07-15	2021-07-09	Modified Shenling Baizhu Powder in the Treatment of Ulcerative Colitis in the Remission Phase: a Ser ...	Modified Shenling Baizhu Powder in the Treatment of Ulcerative Colitis in the Remission Phase: a Ser ...	Ulcerative Colitis	Experimental group:SLBZP Granule and Mesalazine;Control group:Mesalazine;	The First Affiliated Hospital of Guangzhou University of Chinese Medicine	NULL	Pending	18	75	Both	Experimental group:3;Control group:3;	N/A	China
5	ChiCTR2100048502	2021-07-15	2021-07-09	Modified Shenling Baizhu Powder in the Treatment of Ulcerative Colitis in the Remission Phase: a Ser ...	Modified Shenling Baizhu Powder in the Treatment of Ulcerative Colitis in the Remission Phase: a Ser ...	Ulcerative Colitis	Experimental group:SLBZP Granule and Mesalazine;Control group:Mesalazine;	The First Affiliated Hospital of Guangzhou University of Chinese Medicine	NULL	Pending	18	75	Both	Experimental group:3;Control group:3;	N/A	China
6	ChiCTR2100048176	2021-07-12	2021-07-04	A randomized controlled trial of Xuyan decoction in the treatment of ulcerative colitis with spleen ...	A randomized controlled trial of Xuyan decoction in the treatment of ulcerative colitis with spleen ...	Ulcerative colitis	Experimental group:Xuyan Decoction;Control group:Mesalazine sustained-release granules;	Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine	NULL	Pending	18	65	Both	Experimental group:44;Control group:44;		China
7	ITMCTR2100005012	2021-07-12	2021-07-04	A randomized controlled trial of Xuyan decoction in the treatment of ulcerative colitis with spleen ...	A randomized controlled trial of Xuyan decoction in the treatment of ulcerative colitis with spleen ...	Ulcerative colitis	Control group:Mesalazine sustained-release granules;Experimental group:Xuyan Decoction;	Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine	NULL	Pending	18	65	Both	Control group:44;Experimental group:44;		China
8	ChiCTR2100046446	2021-07-01	2021-05-15	Effect of probiotics supplementation combined with WeChat platform health management on nutritional ...	Effect of probiotics supplementation combined with WeChat platform health management on nutritional ...	ulcerative colitis	experimental group:Bifidobacterium triple live bacteria combined with WeChat platform for health man ...	Affiliated Hospital of Jiangnan University	NULL	Recruiting	18	80	Both	experimental group:70;control group:70;	N/A	China
9	EUCTR2019-003334-16-LV (EUCTR)	29/04/2021	14/01/2021	Novel budenosid suppository in addition to basic therapy with oral mesalazinecompared to basic thera ...	Randomised, double-blind, placebo-controlled, multicentre study to compare the efficacy and safety o ...	acute ulcerative colitis MedDRA version: 20.1;Level: LLT;Classification code 10066678;Term: Acute ul ...	Product Name: Budenofalk® suppositories INN or Proposed INN: BUDESONIDE Other descriptive name: Budeno ...	Dr. Falk Pharma GmbH	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	360	Phase 3	Belarus;Poland;Ukraine;Bulgaria;Russian Federation;Germany;Latvia
10	EUCTR2019-003334-16-BG (EUCTR)	11/03/2021	02/12/2020	Novel budenosid suppository in addition to basic therapy with oral mesalazinecompared to basic thera ...	Randomised, double-blind, placebo-controlled, multicentre study to compare the efficacy and safety o ...	acute ulcerative colitis MedDRA version: 20.1;Level: LLT;Classification code 10066678;Term: Acute ul ...	Product Name: Budenofalk® suppositories INN or Proposed INN: BUDESONIDE Other descriptive name: Budeno ...	Dr. Falk Pharma GmbH	NULL	Not Recruiting			Female: yes Male: yes	360	Phase 3	Belarus;Poland;Ukraine;Russian Federation;Bulgaria;Germany;Latvia

First Previous1 2 3 4 5…24Next Last